Cited by 231Cholinesterase and Neurodegenerative DiseasesAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.

Cholinesterase Inhibitors and Beyond

Pepeu, Giancarlo, Giovannini, Maria·2009·Current Alzheimer Research

DOI 10.2174/156720509787602861

Open this paper in CoChat — free account

Abstract

Cholinesterase inhibitors (ChEIs) were introduced in the therapy of Alzheimer Disease (AD) in the nineteen nineties with great expectations. The hopes and large interest raised by these drugs are well demonstrated by 12,000 references listed by PubMed under 'ChEI' for 1995-2007. The list is reduced to 2500 if we confine ourselves to 'ChEIs and dementia'. Of them, about 500 were published in the last two years. Whereas an increase in brain acetylcholine and an improvement of cognitive deficits have been consistently demonstrated in animal models of AD, from aging rats to transgenic mice, the clinical effectiveness of ChEIs has been and is still a matter of contrasting opinions. These range from the negative conclusions of the AD2000 trial on donepezil, claiming that it is not cost effective, with benefits below a minimally relevant threshold, to the NICE appraisal of 2007 declaring that donepezil, rivastigmine, galantamine are efficacious for mild to moderate AD, irrespective of their different selectivity for acetyl- (AChE) and butyrylcholinesterase (BuChE). The possibility that ChEIs may exert their effects through mechanisms beyond cholinesterase inhibition has been envisaged. However, according to the information presented in this review, the "classical" ChEIs, donepezil, rivastigmine and galantamine, show no pharmacological actions beyond cholinesterase inhibition which may play an important role in their therapeutic efficacy. The diverging opinions on clinical efficacy do not discourage from developing new ChEIs, and particularly the so called multifunctional ChEIs. They represent the future of the cholinergic therapy for AD but other indications for these drugs may be considered, including vascular dementia, mild cognitive impairment, and the ethically sensitive improvement of memory and learning in healthy subjects.

Integrity signals

Registry

Crossref · 10.2174/156720509787602861

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198 · cited 1×
“[19, 20]).”
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer Type
Summers, W. K., Majovski, L. V., Marsh, G. M., Tachiki, K. H., & Kling, A. S. (1986) · New England Journal of Medicine · doi:10.1056/nejm198611133152001 · Cited by 1,161
Acetylcholinesterase Accelerates Assembly of Amyloid-β-Peptides into Alzheimer's Fibrils: Possible Role of the Peripheral Site of the Enzyme
Inestrosa, N. C., Alvarez, A. R., Pérez, C. A., Moreno, R. D., Vicente, M., Linker, C., Casanueva, O. I., Soto, C. A., & Garrido, J. (1996) · Neuron · doi:10.1016/s0896-6273(00)80108-7 · Cited by 1,117
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial Commentary: Another piece of the Alzheimer's jigsaw
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
Release of Alzheimer Amyloid Precursor Derivatives Stimulated by Activation of Muscarinic Acetylcholine Receptors
Nitsch, R. M., Slack, B. E., Wurtman, R. J., & Growdon, J. H. (1992) · Science · doi:10.1126/science.1411529 · Cited by 898
Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent
Greig, N. H., Utsuki, T., Ingram, D. K., Wang, Y., Pepeu, G., Scali, C., Yu, Q.-S., Mamczarz, J., Holloway, H. W., Giordano, T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508575102 · Cited by 753
Self-citation
The Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease: Results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial
Rogers, S. L., & Friedhoff, L. T. (1996) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000106895 · Cited by 743
Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials
Kavirajan, H., & Schneider, L. S. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70195-3 · Cited by 497
Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid ß-protein
Selkoe, D. J. (2001) · Journal of Alzheimer's Disease · doi:10.3233/jad-2001-3111 · Cited by 466
A Structural Motif of Acetylcholinesterase That Promotes Amyloid β-Peptide Fibril Formation
Ferrari, G. V. D., Canales, M. A., Shin, I., Weiner, L. M., Silman, I., & Inestrosa, N. C. (2001) · Biochemistry · doi:10.1021/bi0101392 · Cited by 415
Galantamine
Scott, L. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200060050-00008 · Cited by 383
Acetylcholinesterase inhibitors: novel activities of old molecules
Racchi, M. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2003.12.027 · Cited by 291
Selectivity of Cholinesterase Inhibition
Weinstock, M. (1999) · CNS Drugs · doi:10.2165/00023210-199912040-00005 · Cited by 283
Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia
Mesulam, M. M., & Geula, C. (1994) · Annals of Neurology · doi:10.1002/ana.410360506 · Cited by 259
Neuroglial cholinesterases in the normal brain and in Alzheimer's disease: Relationship to plaques, tangles, and patterns of selective vulnerability
Wright, C. I., Geula, C., & Mesulam, M.-M. (1993) · Annals of Neurology · doi:10.1002/ana.410340312 · Cited by 237
Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease
Maelicke, A., & Albuquerque, E. X. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00093-5 · Cited by 224
Design, Synthesis, and Biological Evaluation of Dual Binding Site Acetylcholinesterase Inhibitors: New Disease-Modifying Agents for Alzheimer's Disease
Muñoz-Ruiz, P., Rubio, L., García‐Palomero, E., Dorronsoro, I., del Monte-Millán, M., Valenzuela, R., Usán, P., de Austria, C., Bartolini, M., Andrisano, V., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0503289 · Cited by 221
Effects of Rivastigmine on Cognitive Function in Dementia with Lewy Bodies: A Randomised Placebo-Controlled International Study Using the Cognitive Drug Research Computerised Assessment System
Wesnes, K. A., McKeith, I. G., Ferrara, R., Emre, M., del Ser, T., Spano, P., Cicin-Sain, A., Anand, R., & Spiegel, R. (2002) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000048651 · Cited by 209
Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors
Castro, A., & Martinez, A. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778792985 · Cited by 207
Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors
Barnes, C. A., Meltzer, J., Houston, F. P., Orr, G. W., McGann, K., & Wenk, G. L. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00180-9 · Cited by 193
Cholinesterases and the Pathology of Alzheimer Disease
Geula, C., & Mesulam, M. ‐. (1995) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199501002-00005 · Cited by 193
Metrifonate treatment of the cognitive deficits of Alzheimer's disease
Cummings, J. L., Cyrus, P., Bieber, F., Mas, J., Orazem, J. P., Gulanski, B., & The Metrifonate Study Group* (1998) · Neurology · doi:10.1212/wnl.50.5.1214 · Cited by 173
Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease
Bohnen, N. I. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.038729 · Cited by 160
Current Research in Alzheimer Therapy
Frost, F. S. (1989) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/00002060-198910000-00019 · Cited by 145
Tacrine restores cholinergic nicotinic receptors and glucose metabolism in alzheimer patients as visualized by positron emission tomography
Nordberg, A. K., Lilja, A., Lundqvist, H., Hartvig, P., Amberla, K., Viitanen, M. H., Berglund, U. W., Johansson, M., Hellström‐Lindahl, E., Bjurling, P., et al. (1992) · Neurobiology of Aging · doi:10.1016/0197-4580(92)90099-j · Cited by 141
Regional Effects of Donepezil and Rivastigmine on Cortical Acetylcholinesterase Activity in Alzheimer’s Disease
Kaasinen, V., Någren, K., Järvenpää, T., Roivainen, A., Yu, M., Oikonen, V., Kurki, T. J. I., & Rinne, J. O. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200212000-00012 · Cited by 138
Mechanisms Behind the Neuroprotective Actions of Cholinesterase Inhibitors in Alzheimer Disease
Nordberg, A. K. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213804.59187.2d · Cited by 134
The Experimental Alzheimer’s Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-β Peptide Levels in Cell Culture and Mice
Lahiri, D. K., Chen, D., Maloney, B., Holloway, H. W., Yu, Q.-S., Utsuki, T., Giordano, T., Sambamurti, K., & Greig, N. H. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.112102 · Cited by 134
Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model
Dam, D. V., Abramowski, D., Staufenbiel, M., & Deyn, P. P. D. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2132-z · Cited by 132
Acetylcholinesterase-Aβ Complexes Are More Toxic than Aβ Fibrils in Rat Hippocampus
Reyes, A. E., Chacón, M. A., Dinamarca, M. C., Cerpa, W. F., Morgan, C., & Inestrosa, N. C. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63774-1 · Cited by 129
Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer’s disease
Martı́nez, A., & Castro, A. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.1.1 · Cited by 127
Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer’s disease
Dong, H., Csernansky, C. A., Martin, M. V., Bertchume, A., Vallera, D., & Csernansky, J. G. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2230-6 · Cited by 116
Physostigmine and galanthamine: probes for a novel binding site on the alpha 4 beta 2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells.
Pereira, E. F. R., Alkondon, M., Reinhardt, S., Maelicke, A., Peng, X., Lindström, J., Whiting, P. J., & Albuquerque, E. X. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22435-1 · Cited by 108
An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors
Braida, D., Paladini, E., Griffini, P., Lamperti, M., Maggi, A., & Sala, M. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00072-6 · Cited by 107
Effect of metrifonate on extracellular brain acetylcholine and object recognition in aged rats
Scali, C., Giovannini, M. G., Bartolini, L., Prosperi, C., Hinz, V. C., Schmidt, B. H., & Pepeu, G. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)00128-3 · Cited by 101
Self-citation
Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats
Liang, Y. Q., & Tang, X. C. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2003.12.071 · Cited by 96
The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex
Giacobini, E., Zhu, X., Williams, E., & Sherman, K. (1996) · Neuropharmacology · doi:10.1016/0028-3908(95)00157-3 · Cited by 89
E2020 — The Pharmacology of a Piperidine Cholinesterase Inhibitor
Rogers, S. L., Yamanishi, Y., & Yamatsu, K. (1991) · Birkhäuser Boston eBooks · doi:10.1007/978-1-4899-6738-1_33 · Cited by 88
A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066
Snape, M., Misra, A., Murray, T. K., Souza, R. J. D., Williams, J. L., Cross, A. J., & Green, A. R. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(98)00164-6 · Cited by 85
Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles
Eskander, M. F., Nagykery, N. G., Leung, E. Y., Khelghati, B., & Geula, C. (2005) · Brain Research · doi:10.1016/j.brainres.2005.08.039 · Cited by 83
A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice
Sweeney, J. E., Höhmann, C. F., Moran, T. H., & COYLE, J. T. (1988) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(88)90325-5 · Cited by 82
Comparison of Galantamine and Donepezil for Effects on Nerve Growth Factor, Cholinergic Markers, and Memory Performance in Aged Rats
Hernandez, C. M., Gearhart, D. A., Parikh, V., Hohnadel, E. J., Davis, L. W., Middlemore, M.-L., Warsi, S., Waller, J. L., & Terry, A. V. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.093047 · Cited by 79
Amyloid Precursor Protein in Platelets of Patients With Alzheimer Disease
Borroni, B., Colciaghi, F., Pastorino, L., Pettenati, C., Cottini, E., Rozzini, L., Monastero, R., Lenzi, G. L., Cattabeni, F., Luca, M. D., et al. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.442 · Cited by 79
Anti-dementia drugs and hippocampal-dependent memory in rodents
Yuede, C. M., Dong, H., & Csernansky, J. G. (2007) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282da278d · Cited by 76
Non-cholinergic Effects of Huperzine A: Beyond Inhibition of Acetylcholinesterase
Zhang, H., Yan, H., & Tang, X. C. (2007) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-007-9163-z · Cited by 74
Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer‐like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein
Liskowsky, W., & Schliebs, R. (2006) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2005.11.010 · Cited by 73
A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease
Weinstock, M., Gorodetsky, E. K., Poltyrev, T., Gross, A., Sagi, Y., & Youdim, M. B. H. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00053-8 · Cited by 72
Cholinesterase inhibitor effects on extracellular acetylcholine in rat striatum
Messamore, E. (1993) · Neuropharmacology · doi:10.1016/0028-3908(93)90114-i · Cited by 72
Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C-α in intracerebroventricular β-amyloid-(1–40) infused rats and human embryonic kidney 293 Swedish mutant cells
Zhang, H., Yan, H., & Tang, X. C. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.01.055 · Cited by 70
Nootropic drugs and brain cholinergic mechanisms
Pepeu, G., & Spignoli, G. (1989) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(89)90112-7 · Cited by 69
Self-citation
Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients
Zimmermann, M., Borroni, B., Cattabeni, F., Padovani, A., & Luca, M. D. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.01.002 · Cited by 67
Cholinesterase inhibitors reduce cortical Aβ in dementia with Lewy bodies
Ballard, C. G., Chalmers, K. A., Todd, C. E. C., McKeith, I. G., O'Brien, J. T., Wilcock, G. K., Love, S., & Perry, E. K. (2007) · Neurology · doi:10.1212/01.wnl.0000261920.03297.64 · Cited by 67
Huperzine A attenuates cognitive deficits and hippocampal neuronal damage after transient global ischemia in gerbils.
Zhou, J., Zhang, H.-Y., & Tang, X.-C. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02265-0 · Cited by 66
Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats
Scali, C., Casamenti, F., Bellucci, A., Costagli, C., Schmidt, B. H., & Pepeu, G. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200090 · Cited by 65
Self-citation
Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors.
Weinstock, M., Razin, M., Chorev, M., & Enz, A. (1994) · PubMed · Cited by 64
Psychoactive Drugs and Pilot Performance: A Comparison of Nicotine, Donepezil, and Alcohol Effects
Mumenthaler, M. S., Yesavage, J. A., Taylor, J. L., O'Hara, R. M., Friedman, L., Lee, H., & KRAEMER, H. C. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300202 · Cited by 62
Indicators of neuroprotection with galantamine
Geerts, H. (2004) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2004.11.002 · Cited by 61
Bis(7)-tacrine, a promising anti-Alzheimer's agent, reduces hydrogen peroxide-induced injury in rat pheochromocytoma cells: comparison with tacrine
Xiao, X. Q., Lee, N. T. K., Carlier, P. R., Pang, Y., & Han, Y. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01357-4 · Cited by 59
N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: A comparison with donepezil and rivastigmine
Cerbai, F., Giovannini, M. G., Melani, C., Enz, A., & Pepeu, G. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.06.053 · Cited by 59
Self-citation
Promising anti-Alzheimer’s dimer bis(7)-tacrine reduces β-amyloid generation by directly inhibiting BACE-1 activity
Fu, H., Li, W., Luo, J., Lee, N. T. K., Li, M., Tsim, K. W. K., Pang, Y., Youdim, M. B. H., & Han, Y. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.11.068 · Cited by 56
Cholinesterase Inhibitors Do More than Inhibit Cholinesterase
Giacobini, E. (1997) · Birkhäuser Boston eBooks · doi:10.1007/978-1-4612-4116-4_29 · Cited by 50
Cholinesterases in human brain: the effect of cholinesterase inhibitors on Alzheimer's disease and related disorders
Giacobini, E. (2006) · CRC Press eBooks · doi:10.1201/b14486-19 · Cited by 50
Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students.
Sun, Q. Q., Xu, S., Pan, J. L., Guo, H. M., & Cao, W. Q. (1999) · PubMed · Cited by 47
Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer’s disease
Dam, D. V., Coen, K., & Deyn, P. P. D. (2007) · Psychopharmacology · doi:10.1007/s00213-007-1010-x · Cited by 44
Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: A clinical report series
Spiridigliozzi, G. A., Heller, J. H., Crissman, B. G., Sullivan‐Saarela, J. A., Eells, R. L., Dawson, D., Li, J., & Kishnani, P. S. (2007) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31790 · Cited by 43
Imaging treatment effects in Alzheimer's disease
Venneri, A. (2007) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2007.02.004 · Cited by 43
Eptastigmine: Ten Years of Pharmacology, Toxicology, Pharmacokinetic, and Clinical Studies
Braida, D., & Sala, M. (2001) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2001.tb00205.x · Cited by 42
Effects of donepezil, nicotine and haloperidol on the central serotonergic system in mice: Implications for Tourette's syndrome
Hayslett, R. L., & Tizabi, Y. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.06.010 · Cited by 40
Cerebral glucose metabolism, cerebrospinal fluid-β-amyloid1–42 (CSF-Aβ42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients
Stefanova, E. D., Blennow, K., Almkvist, O., Hellström‐Lindahl, E., & Nordberg, A. K. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(02)01384-8 · Cited by 40
Two-Year Treatment of Alzheimer’s Disease with Eptastigmine
Imbimbo, B. P., Verdelli, G., Martelli, P., Marchesini, D., & and the Eptastigmine Study Group (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017114 · Cited by 38
Second generation cholinesterase inhibitors: Effect of (L)‐huperzine‐A on cortical biogenic amines
Zhu, X. ‐., & Giacobini, E. (1995) · Journal of Neuroscience Research · doi:10.1002/jnr.490410613 · Cited by 38
Complementary and Alternative Medicines in the Treatment of Dementia
Diamond, B. J., Johnson, S. K., Torsney, K., Morodan, J., Prokop, B. J., Davidek, D., & Kramer, P. (2003) · Drugs & Aging · doi:10.2165/00002512-200320130-00003 · Cited by 36
Add-on Therapy With Acetylcholinesterase Inhibitors for Memory Dysfunction in Schizophrenia
Stip, É., Sepehry, A. A., & Chouinard, S. (2007) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e318059be76 · Cited by 35
Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain
Enz, A., & Gentsch, C. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.04.009 · Cited by 34
Nonmedical Influences on the Use of Cholinesterase Inhibitors in Dementia Care
Franz, C. E., Barker, J. C., Kravitz, R. L., Flores, Y. G., Krishnan, S., & Hinton, L. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181461955 · Cited by 32
Neuroprotection via inhibition of nitric oxide synthase by bis(7)-tacrine
Li, W., Lee, N. T. K., Fu, H., Kan, K. K. W., Pang, Y., Li, M., Tsim, K. W. K., Li, X., & Han, Y. (2006) · Neuroreport · doi:10.1097/01.wnr.0000209014.09094.72 · Cited by 28
Chronic treatments with tacrine and (−)-nicotine induce different changes of nicotinic and muscarinic acetylcholine receptors in the brain of aged rat
Zhang, X., Tian, J., Svensson, A., Gong, Z., Meyerson, B. J., & Nordberg, A. K. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200030 · Cited by 25
Cerebral Acetylcholinesterase Imaging: Development of the Radioprobes
Kikuchi, T., Okamura, T., Fukushi, K., Takahashi, K., Toyohara, J., Okada, M., Zhang, M., & Irie, T. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607782507466 · Cited by 25
The acetylcholinesterase inhibitor, ENA 713 (Exelon), attenuates the working memory impairment induced by scopolamine in an operant DNMTP task in rats
Ballard, T. M., & McAllister, K. H. (1999) · Psychopharmacology · doi:10.1007/s002130051082 · Cited by 24
Effects on Cholinergic Markers in Rat Brain and Blood after Short and Prolonged Administration of Donepezil
Haug, K. H., Bogen, I. L., Osmundsen, H., Walaas, I., & Fonnum, F. (2005) · Neurochemical Research · doi:10.1007/s11064-005-8828-6 · Cited by 24
Spatial discrimination deficits by excitotoxic lesions in the Morris water escape task
Spowart-Manning, L., & van der Staay, F. J. (2004) · Behavioural Brain Research · doi:10.1016/j.bbr.2004.05.031 · Cited by 24
Tetrahydroaminoacridine induces opposite changes in muscarinic and nicotinic receptors in rat brain
Nilsson-Håkansson, L., Lai, Z., & Nordberg, A. K. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90448-f · Cited by 22
Tetrahydroaminoacridine and Alzheimer's disease
Byrne, E. J., & Arie, T. (1994) · BMJ · doi:10.1136/bmj.308.6933.868 · Cited by 21
In vivo neurochemical effects of the acetylcholinesterase inhibitor ENA713 in rat hippocampus
Trabace, L., Coluccia, A. M. L., Gaetani, S., Tattoli, M., Cagiano, R., Pietra, C., Kendrick, K. M., & Cuomo, V. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02266-6 · Cited by 21
Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice
Parnetti, L., Lanari, A., Saggese, E., Spaccatini, C., & Gallai, V. (2003) · Neurological Sciences · doi:10.1007/s10072-003-0129-8 · Cited by 21
Effect of subchronic treatment with metrifonate and tacrine on brain cholinergic function in aged F344 rats
Giovannini, M. G., Scali, C., Bartolini, L., Schmidt, B. H., & Pepeu, G. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00429-4 · Cited by 17
Self-citation
CHF2819: Pharmacological Profile of a Novel Acetylcholinesterase Inhibitor
Trabace, L., Cassano, T., Loverre, A., Steardo, L., & Cuomo, V. (2002) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2002.tb00215.x · Cited by 15
Prescription patterns and efficacy of drugs for patients with dementia: physicians’ perspective in Italy
Frisoni, G. B., Canu, E., Geroldi, C., Brignoli, B., Anglani, L., Galluzzi, S., Zacchi, V., & Zanetti, O. O. (2007) · Aging Clinical and Experimental Research · doi:10.1007/bf03324714 · Cited by 15
Donepezil in the Treatment of Narcolepsy
Niederhofer, H. (2006) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.26438 · Cited by 14
Effects of chronic metrifonate treatment on cholinergic enzymes and the blood–brain barrier
Rakonczay, Z., & Papp, H. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00006-7 · Cited by 13
Neurochemical and neurobehavioral effects of ganstigmine (CHF2819), a novel acetylcholinesterase inhibitor, in rat prefrontal cortex: An in vivo study
Trabace, L., Cassano, T., Colaianna, M., Castrignanò, S., Giustino, A., Amoroso, S., Steardo, L., & Cuomo, V. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.07.006 · Cited by 12
Repeated administration of tacrine to normal rats: Effects on cholinergic, glutamatergic, and GABAergic receptor subtypes in rat brain using receptor autoradiography
Sihver, W., Günther, P., Schliebs, R., & Bigl, V. (1997) · Neurochemistry International · doi:10.1016/s0197-0186(97)00010-7 · Cited by 12
Ameliorating Effects of SDZ ENA 713 on Age-Associated Decreases in Learning Performance and Brain Choline Acetyltransferase Activity in Rats
Ohara, T., Fukaya, H., Tanaka, K., & Seno, N. (1997) · Brain Research Bulletin · doi:10.1016/s0361-9230(96)00349-8 · Cited by 11

Sorted by citations

The cholinergic system in aging and neuronal degeneration
Schliebs, R., & Arendt, T. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.058 · Cited by 1,047
Modes and models of forebrain cholinergic neuromodulation of cognition
Hasselmo, M. E., & Sarter, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.104 · Cited by 733
Acetylcholinesterase inhibition-based biosensors for pesticide determination: a review.
Pundir, C., & Chauhan, N. (2012) · Analytical Biochemistry · doi:10.1016/j.ab.2012.06.025 · Cited by 313
Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer’s disease
Guzior, N., Wi.eckowska, A., Panek, D., & Malawska, B. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106122628 · Cited by 323
Revisiting the role of acetylcholinesterase in Alzheimer’s disease: cross-talk with P-tau and β-amyloid
García‐Ayllón, M. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00022 · Cited by 303

See all 231

Authors: Pepeu, G., & Giovannini, M.
Affiliations: University of Florence (IT)
Corresponding author: Giovannini, Maria
ORCID: Giovannini, Maria
Venue: Current Alzheimer Research
Publisher: Bentham Science Publishers Ltd.
Published: 2009-04-01
Volume: 6
Issue: 2
Pages: 86-96
ISSN: 1567-2050 (ISSN-L)
DOI: 10.2174/156720509787602861
OpenAlex: W2133779850
Cited by: 209
References: 96
Citations by year: 2026: 3 · 2025: 6 · 2024: 9 · 2023: 7 · 2022: 10 · 2021: 1 · 2020: 12 · 2019: 13 · 2018: 8 · 2017: 8 · 2016: 15 · 2015: 19 · 2014: 22 · 2013: 12 · 2012: 19
FWCI: 15.57
Type: journal article
Language: en
Open access: closed
Locations: Current Alzheimer Research (publishedVersion)
PubMed (publishedVersion)
Florence Research (University of Florence) (submittedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: cholinesterase inhibitors, Alzheimer's disease, donepezil, rivastigmine, galantamine, acetylcholinesterase, butyrylcholinesterase, cholinergic therapy, vascular dementia, mild cognitive impairment, memory enhancement, clinical efficacy
MeSH terms: Acetylcholine, Alzheimer Disease, Animals, Brain, Cholinesterase Inhibitors, Cholinesterases, Clinical Trials as Topic, Cognition Disorders, Humans, Antipsychotic Agents, History, 20th Century, History, 21st Century

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cholinesterase Inhibitors and Beyond

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks